Podcasts about iols

At the Ophthalpreneurs 2025 meeting in Italy, Dr Ben LaHood (Australia) hosted a discussion with ophthalmologists Mr Kieren Darcy (UK) and Dr Andrzej Dmitriew (Poland) about the evolving landscape of premium IOLs and the transition from diffractive to refractive technology with the introduction of RayOne Galaxy, the world's first spiral IOL. The conversation delved into the impact of bothersome dysphotopsia on patient satisfaction and how the RayOne Galaxy lens addresses common issues like halos and glare whilst delivering full range of vision. The surgeons also shared real-world experiences with the lens, including cases involving family members and a Masterchef celebrity, along with the outcomes they've observed. Dr Dmitriew further discussed his role as a Rayner Centre of Excellence and how integrating the Sophi Phaco System has the potential to enhance surgical outcomes in his practice.   This podcast is provided for general information purposes only. The presenters' views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries. © 2025 Rayner Group, all rights reserved. Rayner, RayOne and Galaxy are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

In this episode of Four Eyes, we sit down with Dr. Marcella LaBelle, an optometrist in Alberta with over 20 years of experience in refractive surgical care, to dive into the world of intraocular and light-adjustable lenses. From identifying ideal candidates (even those without cataracts) to demystifying premium IOLs and new technologies on the horizon, Dr. LaBelle shares expert insights every primary care OD should hear. We also discuss what makes the light-adjustable lens a game-changer for those with advanced dry eyes and corneal issues. Tune in for a sharp, informative discussion packed with clinical pearls you won't want to miss! For more information, contact Dr. Labelle: Marcella.labelle@claritylaservision.com The Four Eyes Podcast is brought to you by YoungOD Connect

In this episode of the ESCRS IME podcast series on refractive IOLs, Drs. Ramza Diamanti and Nic Reus share expert insights on guiding cataract patients through presbyopia correction and the lens selection journey. They discuss when to initiate the conversation, how and when to recommend EDF IOLs, and effective ways to explain associated costs, risks, and benefits. The discussion also covers managing patient expectations, identifying red flags for EDF lens suitability, and practical tips to help maximize patient satisfaction. Don't forget to listen to the other insightful podcasts in the series! Independent medical education supported by Alcon (Gold) and J&J Vision (Gold).

In this episode of the ESCRS IME podcast series on refractive IOLs, Drs. Nic Reus and Ramza Diamanti delve into the crucial role of modern diagnostic tools in achieving precise IOL calculations and selecting the appropriate lens power. They highlight key innovations that improve accuracy and emphasize the importance of axial length measurements and corneal topography in refining IOL power calculations. The discussion also examines the potential consequences of measurement inaccuracies and explores how advancements in IOL power calculation formulas have shaped clinical decision-making and improved outcomes. Don't forget to listen to the other informative podcasts in the series! Independent medical education supported by Alcon (Gold) and J&J Vision (Gold).

In this episode of the ESCRS IME podcast series on refractive IOLs, Drs. Nic Reus and Ramza Diamanti explore the critical steps of the preoperative workup for cataract patients aiming for spectacle independence. They emphasize the importance of thorough preparation to achieve optimal outcomes and explain how residual refractive error can impact both visual performance and patient satisfaction. The discussion also highlights common pitfalls that lead to postoperative refractive surprises, the scenarios in which they are most likely to occur, and practical strategies to minimize the risk. Don't forget to listen to the other insightful podcasts in the series! Independent medical education supported by Alcon (Gold) and J&J Vision (Gold).

Discover the ultimate guide to the top offensive tackles and interior offensive linemen in the 2025 NFL Draft! We look at the top offensive linemen with top 5 rankings for OTs and IOLs in one mega episode!Get to know the players as we explore standout prospects like Will Campbell, Tyler Booker, Armand Membou, Kelvin Banks Jr., Josh Simmons, Josh Conerly Jr., and many more! Gain insights into their strengths, weaknesses, and potential impact on the league as they prepare to be drafted.

Sebastian Frericks, Head of Investor Relations atCarl Zeiss Meditec AG, presents theQ1 2024/25 financial results and discusses revenue growth, market challenges, and future strategies.At the start of the fiscal year,Carl Zeiss Meditec recorded a 3% revenue growth, primarily driven by theDOCTER OPTICS (DO) acquisition. However, underlyingorganic momentum remained negative, as anticipated. The company had previouslyguided for this decline in December, signalling a temporary headwind due to specific market conditions.Despite anegative investment climate in China, with hospitals delaying purchases while awaiting stimulus measures, Carl Zeiss Meditec has shown resilience. Last year's strong post-pandemic delivery phase also meant that this quarter faced a challenging comparison base, but the company has navigated these challenges with determination.Another key issue was theprice decline in intraocular lenses (IOLs) due to China'sVolume-Based Procurement (VBP) regulations, impacting pricing power in this segment. Despite these headwinds, thecompany's order backlog grew by nearly €100 million, reaching€382 million in Q1, signalling stronger demand for future quarters.Notably, the company reported itsfirst consistent order turnaround in 12–18 months, boosting confidence that organic performancehas bottomed out and is set for an upturn.Due to theweak organic performance and product mix effects, particularly lower sales ofhigh-margin surgical microscopes, Carl Zeiss Meditec'sEBITDA declined at the start of the fiscal year. However, theophthalmology division grew by 7%, primarily driven by theDO acquisition. This strategic growth, despite the decline, demonstrates thecompany's forward-thinking approach.Similarly, themicrosurgery division faceda 7.8% organic decline, mainly because of tough comparisons against a strong prior-year period driven by backlog clearance. However, the company is ramping up sales for the next-genKINEVO neurosurgical microscope, expected todrive recovery in the coming quarters.One of thebiggest developments in Q1 2024/25 was theearly approval of VISUMAX 800 in China. Thislatest-generation femtosecond laser system revolutionizes laser vision correction by enabling alenticular cut in 6–8 seconds, significantly enhancingsafety, automation, and patient comfort.Carl Zeiss Meditecmaintains a conservative full-year outlook, citinggeopolitical risks and macroeconomic uncertainties in China. However, stabilization signs insurgical procedure volumes suggest the marketmay have reached its lowest point.Key growth drivers moving forward:✅Stronger order backlog supporting future revenue momentum✅VISUMAX 800 launch in China & US driving market expansion✅KINEVO 900S rollout in neurosurgery boosting high-margin sales✅Potential public stimulus measures in China as a wildcard for upsideFrom amid-term perspective (3–5 years), Carl Zeiss Meditec aims forEBITDA margin recovery to 16–20%, depending onmarket recovery and product adoption.Carl Zeiss Meditec'sQ1 2024/25 results highlight atransitional phase—whileshort-term challenges persist, strategic investments in innovation and operational efficiency position the company forstronger performance ahead.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Professor Graham Barrett, the innovator behind RayOne EMV in partnership with Rayner, joins Mr Alastair Stuart, Medical Director of Optegra UK, in his clinic to discuss why he frequently chooses RayOne EMV for his patients. Mr Stuart shares both his clinical expertise - covering patient selection, calculations, and outcomes - and his personal experience of recommending the lens for his own father's cataract surgery. Together, they examine the lens' advantages in managing spherical aberration, its benefits for post-corneal refractive patients, and how it compares to other intraocular lenses (IOLs) in the field. This podcast is provided for general information purposes only. The presenters' views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries. © 2025 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Introduction to Carl Zeiss Meditec AG by Sebastian Frericks, Head of Investor Relations Sebastian Frericks, Head of Investor Relations, delivered an engaging and insightful presentation on Carl Zeiss Meditec AG, a globally recognised leader in Ophthalmology and Microsurgery. This presentation comprehensively overviewed the company's market position, key strategies, and future growth drivers. The company achieved €2,089 million in revenue in the 2023/24 fiscal year, with a historically solid EBIT margin of 12%. Carl Zeiss Meditec is a market leader with a 40% share in Refractive Surgery and a growing market share in Surgery Anterior (Cataract). Listed on MDAX and TecDAX, Carl Zeiss Meditec is 59% owned by Carl Zeiss AG, a private optics and technology powerhouse. Key Business Segments Ophthalmology - Revenue Contribution: Comprises 77% of total revenue and focuses on diagnosis, treatment, and surgical solutions. - Key Subsegments: - Chronic Disease Management - Refractive Surgery - Cataract Treatment - Retinal Treatment - Market Leadership: Includes a 40% share in Refractive Surgery and a growing share in Anterior Surgery (Cataract). Microsurgery - Revenue Contribution: Contributes 23% of revenue, focusing on high-tech surgical visualisation for Neurosurgery, ENT, Plastic Surgery, and Dentistry. - Market Leadership: ZEISS dominates the microsurgical market with a 60% global share. Geographic Reach and Structural Tailwinds Regional Insights: - The Asia-Pacific region is a key growth driver, accounting for 26% of revenue, with China as the largest single market. - Other significant regions include the US, Germany, and Southeast Asia. Structural Growth Drivers: - Ageing populations lead to increased cataract surgeries. - Rising myopia prevalence, particularly in Asia, where up to 90% of young people have myopia. - Growing demand for digitalised workflows and premium surgical solutions. Innovation and Strategic Investments R&D Investment: Carl Zeiss Meditec commits 16.7% of revenue to R&D. Key Innovations: - VISUMAX®️ 800: A cutting-edge refractive laser surgery system. - KINEVO®️ 900 S: Neurosurgery platform designed for efficiency and better surgical outcomes. - Digital Solutions: Investments focus on connectivity and integrated workflows to enhance clinical outcomes and customer loyalty. Key Growth Drivers - Expansion in emerging markets, including India and Southeast Asia. - Increasing demand for premium intraocular lenses (IOLs) for cataract surgeries, forecasted to grow in unit and revenue share. - Advancements in refractive laser surgery driven by rising global myopia rates. Future Outlook FY 2024/25 Goals: - Moderate revenue growth supported by product launches, including VISUMAX®️ 800 approvals in key markets like the US and China. Macroeconomic Challenges: - Includes constrained consumer spending and investment climates. Profitability Targets: - Long-term EBITA margin target of 16-20%. Conclusion Sebastian Frericks closed the presentation by emphasising Carl Zeiss Meditec's unique market position, strong brand, and commitment to innovation as key factors driving sustainable growth and customer loyalty. This strong brand is a testament to the company's reputation for quality and reliability. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Q&A with Carl Zeiss Meditec AG's Head of Investor Relations, Sebastian Frericks China Market and Recovery Expectations Update on China's Refractive Market and Recovery Expectations for 2024 Market Context: Carl Zeiss Meditec remains the leading player in China's refractive laser surgery market, having experienced over a decade of growth at a CAGR exceeding 20%. However, since China's reopening post-COVID in 2023, the market has faced challenges, including a shift to lower-cost procedures and reduced patient traffic. Utilization rates for installed laser systems declined in the high single digits during late 2024. Seasonality: The refractive business is seasonal, with peaks during Lunar New Year (January-February) and the summer vacation period (July-August). Outlook: A turnaround is expected in the second half of fiscal year 2024/25 with the rollout of the VisuMax 800, an advanced refractive laser platform offering faster and more precise procedures. Despite the current cautious macroeconomic environment, strong indications of clinic demand point to potential growth in late 2025. Trends in Downtrading from SMILE to LASIK in China Observations on Shifts in Procedure Preferences: - Market Shift: The weak consumer environment has shifted preferences from the minimally invasive SMILE therapy to less expensive LASIK procedures. Previously, SMILE accounted for 80% of treatments, but this mix has shifted to 65-70% SMILE and 30-35% LASIK. - Revenue Impact: This mix change has significantly impacted revenue, as SMILE procedures generate higher margins. - Strategic Response: The upcoming VisuMax 800 platform aims to improve the mix by introducing higher-value consumables and addressing the changing consumer landscape. Impact of Volume-Based Procurement (VBP) on IOL Volumes How Has VBP Affected the Intraocular Lens (IOL) Business? VBP Rollout: The Chinese government's volume-based procurement (VBP) system has lowered intraocular lens prices, resulting in significant price reductions across the value chain. While this has pressured margins, volume increases have partially offset the revenue impact. Long-Term Opportunity: With an ageing population and high cataract prevalence, the Chinese market for IOLs has substantial untapped potential. The company expects affordability improvements to drive long-term growth. APAC (Excluding China) Performance Market Dynamics in APAC Regional Highlights: Southeast Asia, including Vietnam, Indonesia, Malaysia, and Singapore, shows strong growth in refractive laser and cataract procedures. India: Economic growth and wealth creation are expected to significantly expand the middle-class market, increasing demand for elective procedures. The company has been directly present in India for over 30 years and is optimistic about its long-term potential. Conclusion Sebastian Frericks highlights Carl Zeiss Meditec AG's resilience amid market challenges, emphasizing the company's strategic positioning, leadership in innovation, and long-term growth potential across global markets. Despite short-term headwinds in China, the company remains optimistic about recovery and expansion opportunities driven by advanced technologies and strong market presence. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Improvements in biometry, the development of more refined multifocal IOLs like the Rayone Galaxy IOL, and societal changes, have led the evolution of cataract surgery into a refractive procedure.Kieren Darcy, one of the UK's leading cataract and refractive surgeons, and Director of The Vision Care Clinic in Bristol, joins us to discuss:* IOL developments and his experience with the Rayone Galaxy IOL* the critical importance of managing ocular surface pathology before surgery* pitfalls to avoid when treating patients who have undergone refractive laser procedures* the potential impact of robotics and AI on cataract surgeryKieren also shares his tips on best refractive surgery outcomes. Including: how to educate patients about IOL options, how to choose lenses which will best meet their visual needs, how to ensure your patients have realistic expectations of their surgery. And he reminds us that “there is no such thing as a free lunch in optics”!You can get full access to Eyes On Tomorrow, including:* Bonus conversations from our guests* PDFs of reading material linked to topics discussed in the podcast and perfect for your CPD* Summaries of the key learnings as a regular newsletter* Discussion with other subscribersThis month's bonus episode discusses considerations and challenges around LASIK surgery, plus the benefits and drawbacks in the emerging field of robotic cataract surgery.All for just £25 per year, when you subscribe at eyesontomorrow.substack.com/subscribeProduced by Matt Hill at Rethink Audio. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit eyesontomorrow.substack.com/subscribe

Carl Zeiss Meditec AG Deep Dive: Q&A Q&A with Carl Zeiss Meditec AG's Head of Investor Relations, Sebastian Frericks US Refractive Market Performance and Competitive Landscape Has refractive competition increased in 2024, particularly from J&J's ELITA or Staar Surgical? - J&J's ELITA: While J&J has entered some markets with their ELITA system, it has yet to gain significant traction in major markets like the US and China due to regulatory hurdles and limited product features. Notably, the system lacks approval for its SILK procedure, which is positioned as a competitor to ZEISS's SMILE therapy. - Staar Surgical: The overlap between ZEISS's laser-based refractive solutions and Staar Surgical's ICL (implantable collamer lens) business is minimal. ICLs cater to niche cases, such as high myopia corrections, where laser-based therapies have limitations. ZEISS maintains a competitive edge in broader applications due to its extensive track record and safety profile, with over 10 million SMILE procedures performed globally. - Strategic Positioning: ZEISS is poised to strengthen its competitive edge with the upcoming rollout of the VisuMax 800, a more advanced platform designed to enhance procedure speed, precision, and patient outcomes. How is your US refractive business performing amid reports of soft demand? - Market Trends: The US market has faced a decline in refractive procedure volumes in 2024 due to high interest rates and reduced consumer spending capacity. Unlike Europe or Asia, a large proportion (approximately 65%) of US refractive procedures are financed, making the market particularly sensitive to macroeconomic conditions. - Outlook: Despite the challenges, the US refractive market holds significant potential. The market size remains underdeveloped relative to historical highs, with 700,000-800,000 annual procedures, far below its peak. ZEISS's technology, particularly the minimally invasive SMILE therapy, is well-positioned to capitalize on market recovery as economic conditions improve and consumer confidence returns. What's your outlook for US equipment sales recovery after Q3 order trends? Stabilization: US equipment sales began stabilizing in Q3 FY24, with improving order entries and a book-to-bill ratio above 1 in the months preceding fiscal year-end. Early trends in FY25 continue to show positive momentum. Growth Drivers: ZEISS is optimistic about growth in FY25, driven by the anticipated FDA approval of the VisuMax 800 platform in mid-2025. The new platform is expected to attract significant demand from clinics aiming to upgrade their technology and enhance patient offerings. What feedback are you getting on the ZEISS cataract workflow? - Market Reception: The ZEISS cataract workflow continues to be well-received, offering a comprehensive and integrated solution for cataract treatment. Feedback highlights the value of combining diagnostic imaging, surgical planning, and premium IOLs (intraocular lenses) within a single platform. Conclusion Sebastian Frericks highlights Carl Zeiss Meditec AG's resilience amidst market challenges, emphasizing the company's strategic initiatives and leadership in innovation. With advanced products like the VisuMax 800 and comprehensive cataract workflows, ZEISS is well-positioned for recovery and long-term growth in the US market. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Strategic Developments and Market Expansion at Carl Zeiss Meditec AG Overview Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, discusses the company's strategic initiatives and recent acquisitions, focusing on the US market rollout of QUATERA 700, the impact of the DORC acquisition, and feedback on the integrated ZEISS cataract workflow. This comprehensive analysis underscores ZEISS's efforts to expand its market potential and strengthen its leadership in ophthalmology and vitreoretinal surgery. Strategic Initiatives and Rollouts Status of QUATERA 700 Rollout and Its Impact on Cataract Surgical Plans QUATERA 700 Introduction: Launched in 2022, the QUATERA 700 fills a critical gap in ZEISS's portfolio as an advanced phacoemulsification (phaco) system for cataract surgery. Challenges: Initial sales have been modest due to delays in obtaining approvals for complementary intraocular lenses (IOLs), particularly premium lenses essential for competitive bundled offerings. Future Plans: ZEISS is heavily investing in R&D to enhance the system's features, accessories, and integration capabilities. The company targets midterm market share gains by leveraging QUATERA's capabilities alongside its broader cataract product suite. Impact of the DORC Acquisition on the Vitreoretinal Market Strategic Fit: The acquisition of Dutch retinal surgery specialist DORC in 2023 has positioned ZEISS as a global leader in vitreoretinal solutions. Opportunities in the US: DORC's established customer base provides ZEISS with an entry point for promoting its IOLs and other complementary products. This synergy is expected to strengthen ZEISS's position in the US market. China Expansion: With its extensive presence and long-standing relationships in China, ZEISS is accelerating DORC's market penetration, leveraging local expertise and distributor networks. Future Integration: The acquisition enables ZEISS to create a comprehensive retinal workflow, combining diagnostic imaging, surgical microscopes, and consumables for improved clinical outcomes. Feedback on ZEISS Cataract Workflow Customer Feedback: The integrated ZEISS cataract workflow has received highly positive feedback for its ability to streamline surgical preparation, reduce complications, and enhance patient outcomes. Efficiency Gains: Studies indicate a 40-50% reduction in surgery preparation and setup time, alongside measurable time savings during procedures due to reduced complications. Market Positioning: ZEISS's fully connected ecosystem of devices and software is becoming the industry standard, setting it apart from competitors offering standalone solutions. Market Potential and Synergies Cross-Selling Opportunities: DORC's retinal customer base offers significant cross-selling potential for ZEISS's cataract solutions, including IOLs and surgical microscopes. Conclusion Carl Zeiss Meditec AG's strategic rollouts, including QUATERA 700 and the integration of DORC, showcase the company's commitment to innovation and market expansion. With a strong focus on delivering comprehensive solutions and leveraging synergies across its portfolio, ZEISS is well-positioned to capitalize on the growing demand in the global ophthalmology and vitreoretinal surgery markets. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG Deep Dive: Q&A Financial and Strategic Outlook: Insights from Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG US Equipment Sales and Market Dynamics Why Were US Equipment Sales, Especially in Microsurgery, Weak in Q3? Market Context: Weakness in microsurgery sales was driven by the late product cycle of older equipment and the launch of the new KINEVO 900 S neurosurgical platform in October 2024. Transition periods between product generations are typically slower. Financing Challenges: Private equity-backed clinics in the US, a significant customer segment, delayed investments due to high interest rates and expectations of an economic turnaround. Recovery Outlook: With the launch of KINEVO 900 S and early stabilization in order entries at the start of FY25, ZEISS anticipates returning to growth in the US market by 2025. Cost-Cutting Plans and Margin Impact Can You Summarize Your Cost-Cutting Plans and Their Impact on Margin Goals? Background: R&D expenses peaked at 17% of sales in FY22 due to investments in digitalization, AI, and cloud-based infrastructure. These investments have built a robust ecosystem of integrated solutions. Optimization Strategy: Adjusted R&D prioritization by focusing on high-impact products. Implemented more responsive planning tools to align R&D investments with market conditions. Reduced or slowed down investments in areas with longer monetization timelines or less immediate commercial potential. Impact on Margins: These adjustments aim to improve productivity and preserve innovation while maintaining ZEISS's leadership as the most R&D-intensive company in the ophthalmology industry. Bridging 2024 Guidance to 2025 Profitability How Do You Bridge 2024 Guidance to the Profitability Step-Up Expected in 2025E? Drivers of Recovery: -Full-year contribution from the DORC acquisition. -Recovery in the Chinese market from inventory destocking. -Continued cost efficiencies in R&D and sales operations. -Stabilized equipment sales and new product launches, including the KINEVO 900 S and QUATERA 700. Macro Conditions: While macroeconomic uncertainty persists, ZEISS expects a gradual improvement in consumer sentiment and demand across key markets. Profitability Targets: The company targets an EBIT margin recovery of 16-20%, depending on macroeconomic developments. R&D Strategy Under Cost Reduction Plan What Is Your R&D Strategy Under the Cost-Reduction Plan, and Where Will Savings Occur? Digital Investments: With foundational investments in cloud infrastructure complete, future spending will focus on developing applications and monetizable use cases. Integration of DORC: Streamlined development plans across cataract and retinal product lines, leveraging synergies from the DORC acquisition. Portfolio Focus: Narrowed the portfolio of premium IOLs to concentrate on high-potential products with the best commercial return. Conclusion With a clear focus on profitability, innovation, and market recovery, Carl Zeiss Meditec AG is well-positioned for long-term growth. The company's strategic initiatives, including the launch of advanced products like the KINEVO 900 S and optimized R&D investments, highlight its resilience and ability to adapt to evolving market dynamics. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ =============================== T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Kendall E. Donaldson, MD, MS, is joined by Marjan Farid, MD, and George O. Waring IV, MD, FACS, to explore the transformative potential of adjustability in IOL technology. The conversation focuses on strategies for patient selection, managing expectations in post-refractive cases, and achieving precise outcomes in complex scenarios with adjustable lenses. Beyond current applications, the discussion expands to future innovations, such as refractive index shaping and modular IOLs, which are poised to reshape cataract and refractive surgery. To explore these topics further, check out the August issue of CRST: https://crstoday.com/articles/aug-2024/the-future-of-iols-embracing-adjustability?single=true.

In this episode of the ESCRS IME podcast series on toric IOLs, Drs. Marjan Farid and Andrzej Dmitriew explore the prevalence of astigmatism in cataract surgery patients and its significant impact on visual quality. They emphasize the importance of comprehensive preoperative assessments, provide key considerations for the decision-making process, and recommend modern IOL power calculation formulas to ensure precise calculations and optimal visual outcomes. Be sure to check out the other insightful episode in this podcast series! Independent medical education supported by Alcon (Platinum) and Zeiss (Bronze).

In this episode of the ESCRS IME podcast series on toric IOLs, Drs. Andrzej Dmitriew and Marjan Farid delve into intraoperative alignment techniques and effective strategies for managing residual astigmatism post-operatively. They highlight the advantages of digital vs manual marking systems, provide practical solutions for addressing refractive surprises, and emphasize the critical importance of correcting the right level of astigmatism. Additionally, they discuss key barriers to toric lens adoption. Don't miss the other informative episode in this podcast series! Independent medical education supported by Alcon (Platinum) and Zeiss (Bronze).

In this episode of the ESCRS IME podcast series on refractive surgery, Drs. Pavol Vesely and Robert Ang delve into the advantages and potential risks of modern refractive surgery techniques. Their discussion highlights LASIK, the growing popularity of lenticular extraction, and phakic IOLs. Additionally, they provide valuable insights into the decision-making process for selecting the most suitable treatment for each patient, considering the diverse range of available options. Don't miss out on the other informative episodes in this podcast series! Independent medical education supported by Johnson & Johnson Vision (Gold), Zeiss (Silver), and STAAR Surgical (Silver).

Patrick Condon is the man who brought phaco to Ireland and who's father, a contemporary of Harold Ridley in London, implanted the 1st IOL in Ireland in 1959.He shares some fascinating insights into those pioneering days of IOLs and phaco surgery and the origins of the feud between Harold Ridley and “The Duke”, which was to shape this story. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit eyesontomorrow.substack.com/subscribe

In this episode of the ESCRS IME podcast series on refractive IOLs, Drs. Joaquín Fernández and Gerd Auffarth discuss the growing use of presbyopia-correcting IOLs, highlighting the benefits of emerging lens options. They emphasize the importance of proper lens selection, patient education, and managing expectations for spectacle independence. Additionally, they share recommendations when selecting trifocal lenses and offer key post-operative strategies to optimize outcomes and enhance patient satisfaction. Don't forget to listen to the other insightful podcasts in this series! Independent medical education supported by Alcon (Platinum), J&J Vision (Bronze) and Zeiss (Bronze).

In this episode of the ESCRS IME podcast series on refractive IOLs, Drs. Gerd Auffarth and Joaquín Fernández discuss effective strategies for educating cataract patients about presbyopia-correcting lenses. They emphasize the importance of evidence-based communication and shared decision-making. Drs. Auffarth and Fernández also offer valuable insights on lens selection, ensuring patients are fully informed about costs and potential risks. Additionally, they address how to manage patient dissatisfaction, even after thorough preoperative counseling. Be sure to listen to the other insightful podcasts in this series! Independent medical education supported by Alcon (Platinum), J&J Vision (Bronze) and Zeiss (Bronze).

In this episode of the ESCRS IME podcast series on refractive IOLs, Prof. Thomas Kohnen and Dr. Basak Bostanci discuss the critical role of precise preoperative measurements in cataract surgery with presbyopia-correcting lenses to prevent postoperative refractive surprises. They explain how residual refractive errors can have a significant impact on patient vision and satisfaction. The discussion also covers common pitfalls that can lead to postoperative refractive issues and offers practical strategies for avoiding them. Be sure to listen to the other informative podcasts in this series! Independent medical education supported by Alcon (Platinum), J&J Vision (Bronze) and Zeiss (Bronze).

The ARRIVE was published in the New England Journal of Medicine on August 8, 2018 1. This study was a large unmasked multicenter trial conducted from March 2014 to August randomized 6,106 nulliparous women to either IOL or expectant management at full term. The trial was conducted at 41 facilities across the United States. This validated that eIOL at 39 weeks, in that patient population, had the ability to reduce cesarean sections and rates of hypertensive diseases of pregnancy. Since that time, elective IOLs have INCREASED at 39 weeks as some messaging was distorted implying that IOL was the BEST way to go over expectant management. Has other data since 2018 found the same thing? Or were the results of the ARRIVE trial an aberration? The ACOG has JUST RELEASED a new CPU which provides additional insights to this. Listen in for details!

Dr Robert Weinstock is a cataract, refractive, and anterior segment surgeon in Largo, Florida, USA and directs a fellowship at the Eye Institute of West Florida, a practice that his father started 50 years ago. He is a big proponent of bimanual phaco which gained in popularity about 15 years ago (even I tried it for a while) and for innovative thinking for complex eyes such as using double toric IOLs in the capsular bag. In this podcast he also shares great insight for young ophthalmologists to maximize the success in their careers. A truly enjoyable podcast with a dear friend -- I am sure you will enjoy it too. We feature a new podcast every week on Sundays and they are uploaded to all major podcast services (click links here: Apple, Google, Spotify) for enjoying as you drive to work or exercise. I am really excited to share these amazing podcasts with you. The full video of the podcast is here on CataractCoach as well as on our YouTube channel. Our podcast is sponsored by Harrow, Inc and we are thankful for their support.

In this episode of AdVANCEd Patient Care, we address dislocated intraocular lenses (IOLs). Though IOLs are intended to be a permanent solution for cataract surgery patients, dislocation can occur, presenting challenges in patient care. Join our doctor panel, as we explore the etiology, clinical presentation, and management strategies for dislocated IOLs. We discuss the latest surgical techniques, post-operative care, and best practices for optimizing patient outcomes. Enhance your understanding and skills in managing dislocated IOLs to ensure the best care for your patients.

In this episode of AdVANCEd Patient Care, we address dislocated intraocular lenses (IOLs). Though IOLs are intended to be a permanent solution for cataract surgery patients, dislocation can occur, presenting challenges in patient care. Join our doctor panel, as we explore the etiology, clinical presentation, and management strategies for dislocated IOLs. We discuss the latest surgical techniques, post-operative care, and best practices for optimizing patient outcomes. Enhance your understanding and skills in managing dislocated IOLs to ensure the best care for your patients.

In this episode of AdVANCEd Patient Care, we address dislocated intraocular lenses (IOLs). Though IOLs are intended to be a permanent solution for cataract surgery patients, dislocation can occur, presenting challenges in patient care. Join our doctor panel, as we explore the etiology, clinical presentation, and management strategies for dislocated IOLs. We discuss the latest surgical techniques, post-operative care, and best practices for optimizing patient outcomes. Enhance your understanding and skills in managing dislocated IOLs to ensure the best care for your patients.

Dr Roger Zaldivar is a refractive and cataract surgeon at the Instituto Zaldivar in Mendoza, Argentina, a multi-generation ophthalmology practice. Recently he has produced an AI method of sizing phakic IOLs like the Visian ICL using image data from ultrasound biomicroscopy (UBM). And his practice now often prefers implanting a phakic IOL instead of corneal laser vision correction and he implants about 1000 phakic lens implants per year. In this podcast we talk all about phakic IOLs, choosing the best refractive procedure for a specific patient, and his path in ophthalmology. We feature a new podcast every week on Sundays and they are uploaded to all major podcast services (click links here: Apple, Google, Spotify) for enjoying as you drive to work or exercise. I am really excited to share these amazing podcasts with you. The full video of the podcast is here on CataractCoach as well as on our YouTube channel. Our podcast is sponsored by Harrow, Inc and we are thankful for their support.

Drs. Kat Talcott and Yoshi Yonekawa join to preview the July 2024 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this episode of the IME podcast on RIOLs, Dr. Basak Bostanci and Prof. Thomas Kohnen discuss available presbyopia-correcting IOLs and critical factors in selecting the most suitable lens for each patient. They highlight the importance of considering the patient's preference for spectacle independence, addressing ocular surface conditions, and potential optical symptoms to maximize patient satisfaction. Independent medical education supported by Alcon (Gold), J&J Vision (Gold) and Zeiss (Bronze).

The toric intraocular lenses (IOL) is a mainstay in the treatment of astigmatism during cataract surgery.  Many people have different thresholds, however, for when they would consider a toric IOL.  What is the appropriate amount of astigmatism that warrants treatment with a toric lens?  Does the threshold vary if a premium lens is being used?  What lens implantation techniques can be implemented to achieve the best possible results with a toric lens?  This episode is sponsored by Sun Pharma Canada - https://sunpharma.com/canada/

Dr Steve Silverstein is an ophthalmologist who has been involved in countless clinical trials in ophthalmology, from new IOLs to innovative surgical technologies to novel pharmacologic products. This clinical trial experience allows him to experience new technologies first and also provides reasonable remuneration to his practice. He also shares his experience in building a very successful practice and how he overcame hurdles and obstacles to truly succeed. So much great material to learn from this one hour conversation. We feature a new podcast every week on Sundays and they are uploaded to all major podcast services (click links here: Apple, Google, Spotify) for enjoying as you drive to work or exercise. I am really excited to share these amazing podcasts with you. The full video of the podcast will also be here on CataractCoach as well as on our YouTube channel. Our podcast is now sponsored by Harrow, Inc and we are thankful for their support.

In this episode of the IME podcast on RIOLs Dr. Basak Bostanci and Susana Marcos discuss the importance of intermediate vision and how to integrate enhanced monofocal IOLs into the presbyopia treatment strategy. Independent medical education supported by Alcon (Gold), J&J Vision (Gold) and Zeiss (Bronze).

Dr Johnny Gayton has an incredible drive and passion which he combines with persistent hard work to truly excel at many fields. He is a true pioneer in cataract surgery and he shared his techniques of piggyback IOLs, lensectomy for treatment of narrow angles, and moving from superior to temporal incisions. He is proof positive that a great work ethic and strong determination are the keys to success. He applied those same principles to become a world class powerlifter in his 50s and then a professional wrestler. I looked up his official bench press record and it is truly outstanding at more than 315 pounds (143 kg) which is 3 plates per side on the Olympic bar set up. For reference, I've been lifting weights my entire adult life and I don't ever bench more than 2 plates per side (225 pounds = 100 kg). In a word, Johnny is amazing and this podcast is on another level: educational, entertaining, and inspiring. We feature a new podcast every week on Sundays and they are uploaded to all major podcast services (click links here: Apple, Google, Spotify) for enjoying as you drive to work or exercise. I am really excited to share these amazing podcasts with you. The full video of the podcast will also be here on CataractCoach as well as on our YouTube channel. Our podcast is now sponsored by Harrow, Inc and we are thankful for their support.

We are joined by Dr. Mike Mahr, an Associate Professor of Ophthalmology at Mayo Clinic. Today we discuss his experience in and research of light adjusted intraocular lenses.  Dr. Mahr will share how this new technology has been pioneered at the Mayo Clinic.  Listen in to understand the opportunity, surgical steps, and clinical adjustments in implementing light adjusted IOLs as you improve the vision of your patients.  Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com  Follow and reach out to us on Twitter: @mayocliniceye 

In this engaging episode of "The History of Eyecare," host Dr. Morgan Micheletti sits down with the esteemed Dr. James Loden, a trailblazer in cataract, refractive, and anterior segment surgery. They explore Dr. Loden's early inspiration from his father and his path to becoming a leading figure in eye care. The episode highlights Dr. Loden's significant contributions to cataract and LASIK surgery, underscoring his innovative approach. The discussion then shifts to Dr. Loden's experiences during his medical training and his involvement in developing new surgical techniques. His reflections on the evolution of ophthalmology provide a unique insight into the challenges and advancements within the specialty. Dr. Loden also shares his experiences in teaching and mentoring, emphasizing the importance of education in his career. Finally, the episode concludes with Dr. Loden sharing his perspectives on the future of eye care. He stresses the importance of patient-focused care, drawing on personal anecdotes and experiences with his mentors. This episode offers a comprehensive look into Dr. Loden's professional journey and his profound impact on ophthalmology.

Dr Kevin Waltz is an ophthalmologist (and optometrist) who has been involved with so many innovative clinical trials of the equipment, IOLs, and technologies that we use in our surgeries every week. He has developed multiple eye surgery centers in other countries where he and his team provide no cost surgery to patients who also can become enrolled in these clinical trials. He has done well by doing good in the world. He is a truly remarkable man and I know that you will thoroughly enjoy this podcast and learn a lot too.

Jack Holladay, MD, MSEE, FACS has done an amazing job of advancing ophthalmology with his engineering mindset and passion for teaching. You have used his invention, the Brightness Acuity Tester (BAT) to help many of your cataract patients and you have benefitted from his Holladay and Holladay 2 equations for IOL calculations with Holladay 3 in the works. He has given a precise explanation of the cause (and solution) to negative dysphotopsias with IOLs in his enigmatic penumbra paper and lecture. This podcast is full of great learning points for your clinic and operating room as well as great personal stories and how he beat incredible odds. 

In this episode, Dr. Morgan Micheletti sits down with Dr. Herbert Gould, a figure who has significantly shaped the landscape of ophthalmology. Dr. Gould takes us on a journey through his career, beginning with his early days in medical school and culminating in his groundbreaking work in introducing intraocular lenses and phacoemulsification to the United States. Along the way, he shares fascinating anecdotes from his time serving in the Air Force, where he had the unique opportunity to interact with Wernher von Braun, the aerospace engineer and space architect. Dr. Gould's multifaceted life extends beyond medicine into the realm of the arts. He talks about his deep-rooted passion for theater, revealing how his artistic pursuits not only enriched his personal life but also had a surprising and beneficial impact on his medical practice. He discusses the challenges he faced in his career, particularly when he was pioneering new surgical techniques. Despite facing skepticism and even professional censure, Dr. Gould remained steadfast in his commitment to advancing the field of ophthalmology. He reflects on the evolution of the medical community's acceptance of new surgical techniques, acknowledging that change often requires a social digestive process that can be time-consuming. Dr. Gould also speaks to the transformative role of women in ophthalmology, celebrating their increasing contributions and even going so far as to say they are braver than their male counterparts when it comes to innovation in the field. Dr. Gould's story is not just a tale of medical advancement, but also one of perseverance, interdisciplinary interests, and the courage to challenge the status quo. His experiences serve as a testament to the importance of maintaining a holistic approach to life and career, embracing challenges as opportunities for growth, and being willing to stand alone in the face of criticism to bring about meaningful change. This episode offers a comprehensive look into the life and contributions of Dr. Herbert Gould, capturing the essence of a man who has not only advanced the field of ophthalmology but has also lived a life rich in experiences and interests outside of medicine. It serves as a valuable historical record, shedding light on the personal and professional elements that have shaped his impactful career.

Cathleen McCabe MD has so many great pearls of wisdom from 25 years in practice including how to manage dislocated IOLs using her belt-loop technique which have featured here. She is a high volume cataract and refractive surgeon and she will hit the 100,000 surgery mark later in her career. She is also scheduled to be ASCRS president in a few years and she was just given the nod to be secretary for that organization. ASCRS apparently no longer does elections and decides on leadership positions via insiders. I look forward to her leadership. This was a very interesting discussion with so many important learning points for ophthalmologists.

For a very complex anterior segment reconstruction surgery, Brandon Ayres MD from Wills Eye Hospital is one of the best, performing many of these tough cases every week. This includes scleral fixated IOLs, prosthetic iris devices, corneal transplantation, pupilloplasty, and more. In this interview he gives a step-wise approach to these tough surgeries and a guideline for success, one step at a time. If you have a tough case coming up, you will benefit so much from this podcast! He also has a great youtube channel where he posts videos of these amazing surgeries. https://www.youtube.com/@brandonayres

Steven Dell MD is a refractive and cataract surgeon in Austin, Texas, USA and he has been involved in so many different avenues of ophthalmology in addition to his clinical practice. More than 15 years ago, he worked with development of the first generation of IOLs which attempted to restore accommodation and we thoroughly discuss this topic in the podcast. He also was founding president of AECOS, the American-European Congress of Ophthalmic Surgery, which promotes innovation, education, and advocacy while also organizing multiple outstanding eye meetings per year in the USA and in Europe. And he is also known for offering guidance and sage advice to younger ophthalmologists as they navigate their careers, me included!

Hosts Trevor Sikkema and Connor Rogers continue their Summer Scouting Series with a super show previewing the offensive line: offensive tackles and interior offensive linemen. The two talk about the names to know for the potential 2024 class, where they stand heading into the 2023 college football season, and give you their Top 5 pre-season OT and IOL rankings for the position. Learn more about your ad choices. Visit megaphone.fm/adchoices

Too busy to read The Lens? Listen to our weekly summary here! In this week's episode, we discuss: The new Assessment of IntraOcular Lens Implant Symptoms questionnaire was shown to effectively evaluate visual symptoms and satisfaction in patients receiving IOLs.  Demographics and social factors are associated with disease severity of microbial keratitis. A new study shows four-point flange intrascleral fixation as a promising technique for plate-haptic trifocal IOL dislocations. Investigating the role of RNA editing on keratins in keratoconus 

The 2023 NFL Draft class has a talented offensive line group with depth. There is a battle for the OT1 spot that could be answered at the NFL Scouting Combine. Broderick Jones has the chance to test better than his counterparts and assume the top place for offensive tackles. Interior offensive linemen are graded as first-round players in this class. Who are they and which tier two IOLs can push to sneak into tier 1? A deep dive is always necessary to identify potential diamonds in the rough. The guys will break down later-round offensive lineman prospects to keep an eye out for. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The 2023 NFL Draft class has a talented offensive line group with depth. There is a battle for the OT1 spot that could be answered at the NFL Scouting Combine. Broderick Jones has the chance to test better than his counterparts and assume the top place for offensive tackles. Interior offensive linemen are graded as first-round players in this class. Who are they and which tier two IOLs can push to sneak into tier 1? A deep dive is always necessary to identify potential diamonds in the rough. The guys will break down later-round offensive lineman prospects to keep an eye out for. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, we are joined by Dr. Brittni Scruggs, assistant professor of ophthalmology and one of the newest members of our Mayo Clinic Ophthalmology retina service team. Dr. Scruggs shares with us the most up to date approaches in the placement of intraocular lenses lacking capsular support. This surgical step continues to be refined in intraocular lens platforms and vitreoretinal surgical safety steps. We are excited to share her perspective with you today!   Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com  Follow and reach out to us on Twitter: @mayocliniceye 

In this second half of a discussion on secondary IOLs, Drs. Brenton Finklea and Fasika Woreta rejoin the show to talk about the benefits and risks of scleral-fixated and scleral-sutured IOLs, and surgical techniques for improving their safety and effectiveness. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

This episode from the archives features Dr. Mitra Ayazifar. Known by her patients as “Dr. Mitra,” she is an experienced eye physician and surgeon specializing in cataract surgery utilizing the most advanced specialty intraocular lenses (IOLs). Dr. Ayazifar holds a Bachelor of Arts degree from the University of California at Berkeley and a Doctor of Medicine degree from the George Washington University School of Medicine and Health Sciences, Washington, D.C., which she earned in 1997. She did her internship in Internal Medicine at Washington Hospital Center in 1998. Other interests include functional and cosmetic eyelid procedures, including ptosis repair (eyelids and brow), blepharoplasty (upper and lower eyelids), and repair of ectropion, entropion, and various eyelid malpositions. Her practice includes general ophthalmology patients and diagnosing and treating various eye conditions, including cataracts, glaucoma, oculoplastic conditions, diabetic retinopathy, and macular degeneration. Contact Dr. Mitra Instagram: https://www.instagram.com/mitramd3/ Social Media Links: https://linktr.ee/DrmitraMd Website: https://www.capeyemed.com/ --- Send in a voice message: https://anchor.fm/urcaringdocs/message